Expression of caveolin-1 enhances cholesterol efflux in hepatic cells by Fu, Y. et al.
Expression of Caveolin-1 Enhances Cholesterol Efflux in
Hepatic Cells*
Received for publication, October 8, 2003, and in revised form, December 23, 2003
Published, JBC Papers in Press, January 16, 2004, DOI 10.1074/jbc.M311061200
Ying Fu‡, Anh Hoang‡, Genevieve Escher‡, Robert G. Parton§, Zygmunt Krozowski‡,
and Dmitri Sviridov‡¶
From the ‡Wynn Domain, Baker Heart Research Institute, Melbourne, Victoria 8008 and the §Institute for Molecular
Bioscience, Center for Microscopy and Microanalysis, and School of Biomedical Science, University of Queensland,
Brisbane, Queensland 4072, Australia
HepG2 cells were stably transfected with human
caveolin-1 (HepG2/cav cells). Transfection resulted in
expression of caveolin-1 mRNA, a high abundance of
caveolin-1 protein, and the formation of caveolae on the
plasma membrane. Cholesterol efflux from HepG2/cav
cells was 280 and 45% higher than that from parent
HepG2 cells when human plasma and human apoA-I,
respectively, were used as acceptors. The difference in
efflux was eliminated by treatment of cells with proges-
terone. There was no difference in cholesterol efflux to
cyclodextrin. Cholesterol efflux from plasma membrane
vesicles was similar for the two cell types. Transfection
led to a 40% increase in the amount of plasma membrane
cholesterol in cholesterol-rich domains (caveolae and/or
rafts) and a 67% increase in the rate of cholesterol traf-
ficking from intracellular compartments to these do-
mains. Cholesterol biosynthesis in HepG2/cav cells was
increased by 2-fold, and cholesterol esterification was
reduced by 50% compared with parent HepG2 cells. The
proliferation rate of transfected cells was significantly
lower than that of non-transfected cells. Transfection
did not affect expression of ABCA1 or the abundance of
ABCA1 protein, but decreased secretion of apoA-I. We
conclude that overexpression of caveolin-1 in hepatic
cells stimulates cholesterol efflux by enhancing transfer
of cholesterol to cholesterol-rich domains in the plasma
membrane.
Cholesterol efflux is the first step in the reverse cholesterol
transport (RCT)1 pathway, removing excess cholesterol from
tissues, including the arterial wall, thus preventing the devel-
opment of atherosclerosis (for review, see Ref. 1). Enhancing
cholesterol efflux from the arterial wall may potentially pre-
vent and even reverse intracellular accumulation of cholesteryl
esters, a hallmark of atherosclerosis. Enhancing cholesterol
efflux from liver cells, the main source of high density lipopro-
tein (HDL), raises plasma HDL concentrations (2) and conse-
quently increases protection against atherosclerosis by RCT
and other mechanisms (3). Enhanced cholesterol efflux can be
achieved either by improving the ability of extracellular accep-
tors to take up cholesterol released from cells or by stimulating
cells to release more cholesterol to plasma acceptors. A number
of approaches have been tested to improve the ability of cells to
release cholesterol. One of these approaches is overexpression
of genes involved in the cholesterol efflux pathways. Overex-
pression of ABCA1 (4), scavenger receptor class B, type I (SR-
BI) (5), or sterol 27-hydroxylase (CYP27A1) (6) enhances cho-
lesterol efflux in vitro. In vivo overexpression of the genes for
ABCA1 (7) and SR-BI (8) leads to increased protection against
atherosclerosis. Stimulation of cholesterol efflux in vitro and
enhanced protection against atherosclerosis in vivo are also
achieved by overexpression of several genes involved in lipopro-
tein metabolism in plasma, but not normally expressed in most
extrahepatic cells. These included apoA-I (9, 10) hormone-sen-
sitive lipase (11), and cholesteryl ester transfer protein (12).
Caveolin-1 is intimately involved in intracellular cholesterol
metabolism pathways (for review, see Ref. 13). It has been
suggested that caveolin is involved in intracellular cholesterol
trafficking (14) and that caveolae are the preferential source of
cholesterol for efflux (15, 16). As an essential component of
caveolae, caveolin is also involved in numerous signaling path-
ways (17). Involvement of caveolin in cholesterol trafficking
makes it a potential target in the search for approaches to
improve cholesterol efflux. There are contradictory reports on
the relevance of the level of caveolin expression to cholesterol
efflux (18–21), with the overall effect most likely to be cell
type-specific. In this work, we demonstrate that overexpression
of caveolin-1 in HepG2 cells results in the formation of caveolae
and enhancement of cholesterol efflux.
MATERIALS AND METHODS
Cells—HepG2 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM), 10% fetal bovine serum, 100 g/ml penicillin/strep-
tomycin, and 2 mM glutamine (all reagents from JRH Biosciences). Cells
were seeded at a density of 1  105 cells/well in a collagen-coated
12-well tissue culture plate and cultured for 24 h to 60–80% confluence.
To obtain stable transfectants, HepG2 cells were transfected with the
pIRES2-EGFP/caveolin-1 plasmid (a gift of Dr. C. Fielding) using Lipo-
fectAMINE Plus reagent (Invitrogen) in serum-free medium for 5 h at
37 °C according to the manufacturer’s recommendations. The transfec-
tion medium was removed, and fresh complete growth medium was
added. Twenty-four hours post-transfection, the cells in one well were
split into 10-cm dishes in medium containing 500 g/ml G418, and the
medium was changed every 3–4 days until G418-resistant colonies
were clearly evident. Individual colonies were picked into 24-well plates
to continue incubation with G418 selection medium. Individual colonies
were evaluated for caveolin expression, and a monoclonal line was used
for all experiments.
Electron Microscopy—Cells were processed for embedding in resin
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and sectioned for electron microscopy exactly as described previously
(22).
Confocal Microscopy—Cells were grown on sterile collagen-coated
glass coverslips to 60% confluence and fixed in acetone for 20 min at
20 °C. Cells were then washed with phosphate-buffered solution
(PBS) and incubated for 1 h with anti-caveolin-1 antibody (Transduc-
tion Laboratories, Lexington, KY). Cells were washed again and incu-
bated in the dark for 30 min with Texas Red-labeled anti-rabbit IgG.
After mounting onto glass slides, cells were observed under a Zeiss
META confocal microscope. Three-dimensional images were recon-
structed from images obtained by serial sectioning.
Cholesterol Acceptors—Blood from healthy normolipidemic volun-
teers (plasma total cholesterol values ranging from 3.4 to 5.0 mmol/
liter) was collected in saline containing streptokinase (final concentra-
tion of 150 units/ml; Sigma), and plasma was isolated by centrifugation
at 1500  g for 15 min at 4 °C. Plasma samples were not pooled, but
rather used individually. ApoA-I was isolated as described previously
(23).
Cholesterol Efflux—Cells were grown to 80% confluence prior to
experiments; the cultures were 100% confluent by the time of incuba-
tion with cholesterol acceptors. To label cellular cholesterol, cultures
were incubated in serum-containing medium with [1,2-3H]choles-
terol (specific radioactivity of 1.81 TBq/mmol, final radioactivity of 74
kBq/ml; Amersham Biosciences) for 48 h in a CO2 incubator. After
labeling, cells were washed six times with PBS and incubated for 18 h
in serum-free medium. For metabolic labeling of cellular cholesterol,
cells were incubated in serum-free Leibovitz L-15 medium with [3H]ac-
etate (specific radioactivity of 95.2 GBq/mmol, final radioactivity of 7.4
MBq/ml; ICN) for 3 h at 15 °C. Cells were washed and incubated for 2 h
at 37 °C in serum-free medium containing lipid-free apoA-I (final con-
centration of 50 g/ml), cyclodextrin (final concentration of 200 g/ml),
or the indicated concentrations of human plasma. When indicated, a
bovine serum albumin (BSA)-progesterone complex (0.5 mg/ml BSA and
10 g/ml progesterone) was added to the incubation medium, and the
same amount of BSA was added to the control incubations. The medium
was then collected and centrifuged at 15,000  g for 15 min at 4 °C to
remove cellular debris, and the supernatant was counted or used for
further analysis. Cells were harvested using a cell scraper and dis-
pensed in 0.5 ml of distilled water, and aliquots were counted or used for
further analysis. Metabolically labeled cholesterol was isolated from
aliquots of the cells and medium by TLC as described previously (24,
25). Cholesterol efflux is expressed as the percentage of labeled choles-
terol transferred from cells to the medium.
Plasma Membrane Vesicle Preparations and Cholesterol Efflux
Therefrom—Plasma membrane vesicles were prepared by the method
originally described by Bellini et al. (26) with modifications introduced
by Gaus et al. (27). In brief, plasma membrane “blebbing” was induced
by incubating cells (labeled with [3H]cholesterol as described above)
with 50 mM formaldehyde and 2 mM dithiothreitol (Sigma). The buffer
was collected; loose cells were removed by centrifugation; and vesicles
were repeatedly centrifuged at 50,000 rpm for 3 h in a Ti-70 rotor to
remove formaldehyde and dithiothreitol. Small vesicles were then re-
moved by concentrating the solution using 0.1-m filters. The plasma
membrane vesicles (20 g of protein) were incubated in 1 ml of DMEM
with or without 5% human plasma for 2 h at 37 °C. The mixture was
then centrifuged through a 0.1-m filter at 400  g for 30 s and rapidly
washed with DMEM. Aliquots of eluted and retained fractions were
counted. The “yield” of separation (y; i.e. amount of plasma protein
eluted through the filter) was determined in a control sample, and
cholesterol efflux was calculated as follows: (eluted [3H]cholesterol/total
[3H]cholesterol)  1/y.
Cholesterol Trafficking—To label the entire cellular cholesterol pool,
cells were incubated in serum-containing medium with [14C]cholesterol
(final radioactivity of 0.2 MBq/ml) for 48 h at 37 °C in a CO2 incubator.
After washing, cells were further incubated in serum-free medium for
18 h at 37 °C in a CO2 incubator. Cells were cooled on ice; [
3H]acetate
(final radioactivity of 7.4 MBq/ml) was added; and cells were further
incubated in Leibovitz L-15 medium for 3 h at 15 °C. Under these
conditions, intracellular cholesterol trafficking is blocked, whereas cho-
lesterol biosynthesis proceeds (28, 29). At the end of the incubation,
cells were quickly warmed and incubated for 20 min at 37 °C to allow a
portion of the newly synthesized cholesterol to be transferred to the
plasma membrane. The cells were cooled on ice and washed three times
with the ice-cold PBS. Cholesterol oxidase (Roche Applied Science) was
added to the cells at a final concentration of 1 unit/ml, and flasks were
incubated for 3 h at 4 °C. Under these conditions, only cholesterol in
plasma membrane cholesterol-rich domains is oxidized (15, 30), forming
cholestenone (referred to as oxysterol throughout), and the reaction is
carried out to completion (15). Lipids were extracted from cells and
analyzed by TLC as described previously (31). “No-oxidase” and “no-
warm-up” controls were included in each experiment. The amount of
oxidizable cholesterol was calculated as the amount of [14C]oxysterol or
[3H]oxysterol as a fraction of the total non-oxidized [3H]cholesterol in
the sample (entire cholesterol pool), thus correcting for losses during
lipid separation. The no-oxidase control, which was 10% of the “oxi-
dized” samples, was subtracted from the experimental values.
Cholesterol Biosynthesis and Esterification—To assess cholesterol
biosynthesis, cells were incubated in serum-free medium with [3H]ac-
etate (final radioactivity of 7.4 MBq/ml) for 20 min at 37 °C in a CO2
incubator. To assess cholesterol esterification, cells were incubated for
2 h at 37 °C with [14C]oleic acid (specific activity of 2.22 GBq/mmol,
final radioactivity of 0.185 MBq/ml; Amersham Biosciences) complexed
with BSA (essentially fatty acid-free; Sigma). Cells were washed, and
lipids were extracted and analyzed by TLC as described previously (24).
Spots of cholesterol and cholesteryl oleate were identified by standards
(Sigma), scraped, and counted in a -counter.
Reverse Transcription (RT)-PCR—Total RNA was extracted from
cells following a modification of the guanidinium thiocyanate method
(32). The RNA concentration was determined by measuring the absorp-
tion at 260 nm. Reverse transcription was carried out in 20 l contain-
ing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl2, 10 mM dithio-
threitol, 40 units of RNase inhibitor, and 50 units of Superscript II
reverse transcriptase (Invitrogen) as described previously (6). PCR was
performed in a total volume of 50 l containing 10 mM Tris-HCl (pH
8.4), 50 mM KCl, 1.5 mM MgCl2, 200 M dNTPS, 100 ng of the
appropriate primers (caveolin 5-primer, GAGGGACATCTCTACACC-
GTTC; and caveolin 3-primer, ACTGAATCTCAA TCAGGAAGCTCT),
2 l of reverse-transcribed cDNA, and 1 units of Taq polymerase
(PerkinElmer Life Sciences). The reaction was amplified with a DNA
thermal cycler (PerkinElmer Life Sciences) for 35 cycles. The amplifi-
cation profile involved denaturation at 94 °C for 30 s, primer annealing
at 58 °C for 30 s, and elongation at 72 °C for 1 min. 10 l of each PCR
reaction was mixed with 2 l of 6-fold concentrated loading buffer and
loaded onto a 1.2% agarose gel containing ethidium bromide. Electro-
phoresis was carried out at a constant voltage of 100 V for 30 min. The
sequences of the fragments amplified by PCR were confirmed by DNA
sequencing.
The amount of ABCA1 mRNA in HepG2 and HepG2/cav cells was
quantified by real-time RT-PCR according to Su et al. (33). Amplifica-
tion of cDNA was from 50 ng of total RNA. The primers used were as
follows: forward, 5-TCCTCTCCCAGAGCAAAAAGC-3; and reverse,
5-GTCCTTGGCAAAGTTCACAAATACT-3. The probe used was 5-
ACTCCACATAGAAGACTACT-3, labeled with carboxyfluorescein and
carboxytetramethylrhodamine at the 5- and 3-ends, respectively. 18 S
rRNA was used as an internal control with the probe labeled with
VIC™ (Applied Biosystems, Foster City, CA) and carboxytetramethyl-
rhodamine at the 5- and 3-ends, respectively. The results are ex-
pressed as Ct (difference between Ct values for ABCA1 and 18 S
RNAs). The interassay variation was 2% as determined on 3 separate
days. The efficiency of the control and ABCA1 probes was similar.
ApoA-I Synthesis and Secretion—HepG2 or HepG2/cav cells were
incubated for 2 h in serum-free medium, and the medium was collected.
Cells were scraped, suspended in 500 l of PBS containing leupeptin
and pepstatin (final concentration of 1 g/ml), and sonicated for 10 s
(50% duty). The suspension was centrifuged for 5 min at 15,000  g,
and the supernatant was taken for analysis. ApoA-I concentration in
the cell lysate and medium was determined by competitive enzyme-
linked immunosorbent assay as described previously (34).
Western Blotting—Cells were lysed in radioimmune precipitation assay
FIG. 1. Expression of caveolin-1 mRNA (A) and protein (B) in
HepG2 and HepG2/cav cells. A, expression of caveolin-1 mRNA was
analyzed by RT-PCR as described under “Materials and Methods.” The
expected size of the amplicon is 394 bp. B, shown is a Western blot of
transfected and non-transfected cells using anti-caveolin-1 antibody.
Lane 1, endothelial cells; lanes 2 and 3, different amounts of HepG2/cav
cells; lane 4, HepG2 cells (same amount of protein as in lane 3).
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buffer, and proteins were separated on a 6% (ABCA1) or 15% (caveolin)
SDS-polyacrylamide gel, followed by immunoblotting using either rabbit
anti-ABCA1 serum (raised against a recombinant fragment of human
ABCA1 (amino acids 1314–1450)) or rabbit anti-human caveolin-1 anti-
body (Transduction Laboratories). Bands were visualized by chemilumi-
nescence development and quantified by densitometry.
Statistical Analysis—All experiments were reproduced two to four
times, and representative experiments are shown. Unless otherwise
indicated, experiments were performed in quadruplicate. Means  S.D.
are presented. Student’s t test was used to determine statistical signif-
icance of the differences.
RESULTS
Stable Transfection of HepG2 Cells with Caveolin-1—When
HepG2 cells were stably transfected with caveolin-1 (HepG2/
cav cells), a strong signal of 394 bp corresponding to caveolin
mRNA was detected by RT-PCR (Fig. 1A, lane 3). Expression of
caveolin was also analyzed by Western blot analysis using
specific anti-caveolin-1 antibody. A single band of 22 kDa mi-
grating at the same position as caveolin from endothelial cells
was detected in HepG2/cav cells (Fig. 1B, lanes 1–3). No ex-
pression of caveolin-1 mRNA or caveolin protein was detected
in non-transfected HepG2 cells (Fig. 1, A and B, lane 4). This
confirms the previous findings of Fujimoto et al. (35) that
HepG2 cells do not normally express caveolin. The plasmid
used for transfection contained green fluorescent protein, ena-
bling evaluation of the efficiency of transfection. After the final
cloning, 90% of the cells expressed green fluorescent protein.
Cells were also treated with anti-caveolin-1 antibody and
studied using confocal microscopy. HepG2/cav cells stained
with anti-caveolin antibody (Fig. 2A), whereas control HepG2
cells showed no staining (data not shown). Caveolin in HepG2/
cav cells was mostly present on the plasma membrane; how-
ever, significant staining was also found in the perinuclear
area. This is consistent with the caveolin present in plasma
membrane caveolae and the Golgi and is similar to the pattern
observed in caveola-rich cholesterol-loaded endothelial cells
(36), smooth muscle cells (37), and mouse peritoneal macro-
phages (38). The pattern of distribution of caveolin between
different regions in the plasma membrane of HepG2/cav cells
was studied by reconstructing three-dimensional confocal im-
ages. Most caveolin was found on the dorsal side of cells, as
evident from three-dimensional (Fig. 2B) and cross-sectional
(Fig. 2C) images as well as well as from quantitative analysis of
the intensity distribution of caveolin-1 staining in transfected
cells (Fig. 2D). Weak staining was found on the ventral parts of
the membrane (Fig. 2, B and C).
The caveolin-1-transfected cells were also examined by elec-
tron microscopy. Surface-connected pits with the typical mor-
phology of caveolae and 65 nm in size were observed in the
FIG. 2. Confocal and electron microscopy of caveolae in HepG2/cav cells. A, confocal microscopy. Cells were fixed in acetone for 20 min,
washed with PBS, incubated with anti-caveolin-1 antibody, washed again, and incubated in the dark with Texas Red-labeled anti-rabbit IgG. Bar
20 m. B, three-dimensional confocal image of a HepG2/cav cell processed as described for A and reconstructed from serial sectioning. Bar  10
m. C, cross-section of the image in C. D, intensity plot of the image in C. Blue and yellow correspond to a low and medium abundance, respectively,
of caveolin in a particular section, and red corresponds to a high abundance of caveolin. E, electron microscopy. Cells were processed for embedding
in Epon, and sections were cut parallel to the substratum. Uncoated flask-shaped pits or vesicular profiles typical of caveolae are evident in the
transfected cells (indicated by arrowheads). These contrast with larger clathrin-coated pits (indicated by arrows). Bars  100 nm.
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transfected cells on both the dorsal surfaces of the cells and in
regions of cell-cell contacts, but not in control cells (Fig. 2E).
However, caveola abundance was low, with, on average, less
than one caveolar profile/cell profile.
Cholesterol Efflux—To evaluate the effect of caveolin expres-
sion on cholesterol efflux, cellular cholesterol was labeled with
[3H]cholesterol, and cells were incubated with human plasma,
lipid-free apoA-I, cyclodextrin, and medium alone. Compared
with HepG2 cells, the efflux from HepG2/cav cells was 80, 280,
and 45% higher (p  0.01 for all) when 5% plasma, 2% plasma,
and 50 g/ml apoA-I, respectively, were used as acceptors (Fig.
3A). There was no significant difference in cholesterol efflux
from the two cell types to cyclodextrin (200 g/ml), a nonspe-
cific cholesterol acceptor. When cellular cholesterol was meta-
bolically labeled with [3H]acetate, the efflux from HepG2/cav
cells to 5% plasma was 20% higher than that from HepG2 cells
(p  0.01) (Fig. 3B).
Intracellular Cholesterol Trafficking—Caveolae are consid-
ered to be a principal source of cholesterol for efflux (15, 16). It
has also been suggested that caveolin is involved in transport-
ing cholesterol from intracellular compartments to the plasma
membrane pool (14), where it becomes accessible for efflux.
Introduction of caveolin into cells not expressing it naturally
and formation of caveolae may also increase the amount of
FIG. 3. Cholesterol efflux to human plasma and lipid-free
apoA-I. Transfected and non-transfected cells were labeled with
[3H]cholesterol (A) or [3H]acetate (B) as described under “Materials and
Methods.” Cells were then incubated with the indicated concentrations
of human plasma, human lipid-free apoA-I (final concentration of 50
g/ml), cyclodextrin (final concentration of 200 g/ml), or serum-free
medium alone for 2 h at 37 °C in a CO2 incubator. A, the medium was
collected; cells were washed; and the amount of radioactivity in the cells
and medium was determined by liquid scintillation spectrometry. B,
cholesterol was isolated from the cells and medium and separated by
TLC as described under “Materials and Methods.” Cholesterol efflux is
expressed as the percentage of labeled cholesterol that moved from cells
to the medium (i.e. radioactivity in the medium/radioactivity in the
medium 	 radioactivity in the cells). Means  S.D. of quadruplicate
determinations are shown. *, p  0.01 versus non-transfected cells.
FIG. 4. Evaluation of the amount of cholesterol in cholesterol-
rich domains (A) and the rate of cholesterol trafficking from the
endoplasmic reticulum to cholesterol-rich domains (B). The en-
tire cellular cholesterol pool was labeled by incubation in serum-con-
taining medium with [14C]cholesterol for 48 h at 37 °C in a CO2 incu-
bator. After washing, cells were further incubated in serum-free
medium for 18 h at 37 °C in a CO2 incubator. Cells were cooled on ice;
[3H]acetate was added; and cells were further incubated for 3 h at 15 °C.
At the end of the incubation, cells were quickly warmed and incubated
for 20 min at 37 °C to allow a portion of the newly synthesized choles-
terol to be transferred to the plasma membrane. The cells were cooled
on ice and washed three times with ice-cold PBS. Cholesterol oxidase
was added to the cells at a final concentration of 1 unit/ml, and flasks
were incubated for 3 h at 4 °C. Lipids were extracted from cells and
analyzed by TLC as described under “Materials and Methods.” The
amount of oxidizable cholesterol was calculated as the amount of
[14C]oxysterol or [3H]oxysterol as a fraction of the total non-oxidized
[14C]cholesterol in the sample (entire cholesterol pool). *, p  0.02.
FIG. 5. Cholesterol efflux from plasma membrane vesicles.
Plasma membrane vesicles were prepared as described under “Materi-
als and Methods.” The vesicles (20 g of protein) were incubated in 1 ml
of DMEM with or without 5% human plasma for 2 h at 37 °C. The
mixture was then centrifuged through a 0.1-m filter at 400 g for 30 s
and rapidly washed with DMEM. Aliquots of eluted and retained frac-
tions were counted. The yield of separation (y; i.e. amount of plasma
protein eluted through the filter) was determined in a control sample,
and cholesterol efflux was calculated as follows: (eluted [3H]cholesterol/
total [3H]cholesterol)  1/y. Background values (e.g. efflux in the ab-
sence of plasma) were subtracted.
FIG. 6. Effect of progesterone on cholesterol efflux from
HepG2 and HepG2/cav cells. Transfected and non-transfected cells
were labeled with [14C]cholesterol (A) or [3H]acetate (B) as described
under “Materials and Methods.” Cells were then incubated with BSA-
progesterone (10 g/ml progesterone (PG)) or BSA alone and 5% human
plasma or with serum-free medium for 1 h at 37 °C in a CO2 incubator.
A, the medium was collected; cells were washed; and the amount of
radioactivity in the cells and medium was determined by liquid scintil-
lation spectrometry. B, cholesterol was isolated from the cells and
medium and separated by TLC as described under “Materials and
Methods.” Cholesterol efflux is expressed as the percentage of labeled
cholesterol that moved from cells to the medium (i.e. radioactivity in the
medium/radioactivity in the medium 	 radioactivity in the cells).
Means  S.D. of quadruplicate determinations are shown. *, p  0.01
versus non-transfected cells.
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cholesterol in pools accessible for efflux. To assess these possi-
bilities, cells were labeled with [14C]cholesterol, allowing la-
beled cholesterol to equilibrate among all cellular pools. Cells
were then treated with cholesterol oxidase under conditions in
which only cholesterol in cholesterol-rich domains on the cell
surface (rafts and/or caveolae) is oxidized. The relative amount
of cholesterol in cholesterol-rich domains in HepG2/cav cells
was 40% higher compared with that in HepG2 cells (p  0.02)
(Fig. 4A). To assess the rate of cholesterol trafficking, cells were
incubated with [3H]acetate for 3 h at 15 °C. Cells were then
warmed up for 20 min at 37 °C to allow newly synthesized
cholesterol to move to the plasma membrane before treatment
of cells with cholesterol oxidase. The amount of newly synthe-
sized [3H]cholesterol that moved to the cholesterol-rich do-
mains in the plasma membrane was 67% higher in HepG2/cav
cells compared with that in HepG2 cells (p  0.02) (Fig. 4B).
These experiments indicate that cholesterol efflux in cells
overexpressing caveolin-1 is enhanced due to increased trans-
fer of cholesterol to plasma membrane pools accessible for
efflux. However, they do not distinguish between contributions
of increased cholesterol flow to these domains and higher
steady-state concentrations of cholesterol in this pool. To in-
vestigate the issue further, we compared the efflux of choles-
terol from plasma membrane vesicles prepared from HepG2
and HepG2/cav cells. Cholesterol efflux from the vesicles, which
reflects the concentration of cholesterol in the plasma membrane
without contribution of cholesterol flow from intracellular com-
partments, was similar for the two cell types (Fig. 5). This is
consistent with a lack of difference between the two cell types in
cholesterol efflux to cyclodextrin, which is an indirect measure
of plasma membrane cholesterol content (Fig. 3A) (39).
Furthermore, we treated cells with progesterone, a potent
inhibitor of intracellular cholesterol trafficking (14, 31). To
minimize nonspecific equilibration of cholesterol between cel-
lular compartments, the duration of efflux incubation was
shortened to 1 h in these experiments, a change in conditions
that affected the magnitude of the difference in efflux from the
two cell types. Nevertheless, the efflux of [14C]cholesterol from
HepG2/cav cells to 5% plasma was significantly higher com-
pared that from parent HepG2 cells; this difference was com-
pletely eliminated in the presence of 10 g/ml progesterone
(Fig. 6A). Progesterone also eliminated the difference in efflux
of intracellular cholesterol after labeling cells metabolically
with [3H]acetate (Fig. 6B). These experiments indicate that
overexpression of caveolin-1 enhances cholesterol efflux mainly
by stimulating intracellular cholesterol trafficking, with appar-
ently increased steady-state concentrations of cholesterol in
plasma membrane cholesterol-rich domains contributing little
to the efflux.
Cholesterol Biosynthesis and Esterification—Cholesterol bio-
synthesis and esterification in HepG2 and HepG2/cav cells
were assessed as an indirect measure of changes in intracellu-
lar cholesterol content. The rate of [3H]acetate incorporation
into cholesterol in HepG2/cav cells was almost twice that in
HepG2 cells (p  0.001) (Fig. 7A). In contrast, the rate of
[14C]oleic acid incorporation into cholesteryl esters in HepG2/
cav cells was 40% lower compared with that in HepG2 cells
(p  0.001) (Fig. 7B).
Cell Proliferation—Caveolin and caveolae are tightly linked
to cell growth by changing cellular cholesterol content (21)
and/or through platelet-derived growth factor signaling (37).
When the rate of proliferation was analyzed in HepG2 and
HepG2/cav cell cultures seeded at the same density, the rate
was significantly slower in HepG2/cav cells. 51% fewer cells
were found in HepG2/cav cultures than in HepG2 cultures after
4 days of culturing, when the cultures were approaching con-
fluency (p  0.001) (Fig. 8). This finding is consistent with
reports of Fielding et al. (21), who demonstrated inhibition of
human skin fibroblast proliferation after transfection with
caveolin-1.
FIG. 7. Cholesterol biosynthesis (A)
and esterification (B) in HepG2 and
HepG2/cav cells. Cells were incubated
in serum-free medium with [3H]acetate
for 20 min (A) or with [14C]oleic acid for
2 h (B) at 37 °C in a CO2 incubator. Cells
were washed. and lipids were extracted
and analyzed by TLC as described under
“Materials and Methods.” *, p  0.001.
FIG. 8. Proliferation of HepG2 and HepG2/cav cells. Cells were
seeded at the same density (1  105 cells/well) in 6-well plates, and the
number of cells was counted every day. , HepG2 cells; E, HepG2/cav
cells.
TABLE I
Synthesis and secretion of apoA-I by HepG2 and HepG2/cav cells
The amount of apoA-I in the cells and medium after a 2-h incubation
was analyzed by competitive enzyme-linked immunosorbent assay as
described under “Materials and Methods.”
Cells Intracellular apoA-I Secreted apoA-I
mg/mg cell protein mg/mg cell protein mg/ml
HepG2 0.25  0.01 2.8  0.2 5.4  0.3
HepG2/cav 0.21  0.12 0.8  0.1a 2.4  1.1b
a p  0.001.
b p  0.01.
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Secretion of ApoA-I—As a hepatic cell line, HepG2 cells pro-
duce and secrete apoB-containing lipoproteins (mainly low den-
sity lipoprotein) and apoA-I (40), which may contribute to the
release of cholesterol from cells. We found that HepG2 cells
produced substantial amounts of apoA-I and that most of this
was secreted into the medium (Table I). However, the amount
of apoA-I secreted by both cell types during a 2-h incubation
was 11% of the amount of exogenous apoA-I added. Interest-
ingly, the amount of apoA-I synthesized and secreted by
HepG2/cav cells was three times lower compared with non-
transfected cells (Table I). Thus, the observed stimulation of
cholesterol efflux is not related to apoA-I synthesis and its
secretion by the cells.
Background efflux (i.e. efflux in the absence of any exogenous
acceptors) was 10% and was similar for the two cell types.
This discounted the possibility that cholesterol released with
secreted apoB- and apoA-I-containing lipoproteins contributed
significantly to the observed differences in cholesterol efflux.
Expression of ABCA1—It was demonstrated by Orso et al.
(41) that mutations of ABCA1 affect caveolin-1 expression and
processing. In view of a possible link between expression of
caveolin and ABCA1, we investigated the effect of stable trans-
fection with caveolin on ABCA1 expression. However, when
analyzed by real-time RT-PCR, no difference in the abundance
of ABCA1 mRNA between the two cell types was found (Fig.
9A). There was also no significant difference in the abundance
of ABCA1 protein as measured by Western blotting, during
which a single band of 220 kDa was observed (Fig. 9B).
DISCUSSION
The major finding of this study is that stable transfection of
HepG2 cells with caveolin-1 enhances cholesterol efflux. The
effect was independent of lipoprotein secretion and ABCA1
expression. Cholesterol efflux is the first step in the RCT path-
way, and the liver is usually considered the destination rather
than the origin of RCT. However, it was recently suggested that
the liver may be the major source of HDL cholesterol in plasma
(7). Thus, the liver may play a dual role in the regulation of
RCT by being both the origin and destination of the pathway.
The effect of transfection of cells with caveolin-1 on intracel-
lular cholesterol metabolism and cholesterol efflux was studied
previously, but the results were inconsistent. Smart et al. (14)
demonstrated that transport of newly synthesized cholesterol
to plasma membrane caveolae is significantly enhanced after
transfection of L1210-JF cells with caveolin. Fielding et al. (21)
demonstrated that transfection of human fibroblasts with
caveolin increases cholesterol efflux. Arakawa et al. (42) dem-
onstrated that inhibition of caveolin-1 expression inhibits cho-
lesterol efflux in THP-1 cells. In contrast, Frank et al. (20)
showed that inhibition of caveolin-1 expression stimulates cho-
lesterol efflux in NIH-3T3 fibroblasts. Matveev et al. (43) did
not observe changes in cholesterol efflux from J774 or RAW
cells after transfection with caveolin. Wang et al. (18) and
Frank et al. (19) also found that transfection of HEK-293T and
FRT cells with caveolin has no effect on cholesterol efflux. The
likely reason for the differences observed is that the role of
caveolin in cholesterol metabolism is cell type-specific. In this
study, we did not observe stimulation of cholesterol efflux after
transient overexpression of human caveolin-1 in CHOP and
RAW 264.7 cells, in which there was at least a 6-fold increase
in cellular caveolin content after transfection (data not shown).
At the same time, overexpression of SR-BI2 or CYP27A1 (6) in
these cells enhances cholesterol efflux. Another example is that
expression of caveolin is down-regulated by HDL in NIH-3T3
fibroblasts (20), but up-regulated by apoA-I in human skin
fibroblasts (31). A possible cause for the cell type-specific dif-
ferences might be the extent of involvement of caveolin and
caveolae in cholesterol efflux and/or the extent of formation of
caveolae after overexpression of caveolin, both of which may
vary widely from one cell type to another. None of the previous
studies evaluated the formation of new caveolae or a change in
abundance of existing caveolae after transfection of cells with
caveolin-1. The presence of caveolin is not always associated
with formation of caveolae (44), and we did not find a dramatic
increase in the number of caveolae after transfection of CHOP
cells with caveolin (data not shown). We have previously dem-
onstrated that caveolin may not only be localized in caveolae,
but may also be present in intracellular lipid bodies and the
Golgi (45). In this study, we found that a proportion of HepG2/
cav cells did not form caveolae, but rather contained caveolin in
intracellular compartments. Distribution of caveolin within the
cell and formation of caveolae may be critical factors regulating
cholesterol efflux. The effect of transfection with caveolin may
also depend on the ability of caveolin-1 to form complexes with
other proteins involved in intracellular trafficking, such as
heat shock protein (46) and caveolin-2 (38). Finally, the results
obtained may depend on the exact pathway investigated in a
particular study. Frank et al. (19) studied SR-BI-dependent
cholesterol efflux in cells overexpressing SR-BI with or without
the concomitant expression of caveolin. The recent findings
that SR-BI may not be co-localized with caveolae (47) and that
caveolae are not required for its proper function (44) suggest
that the SR-BI-dependent pathway might not depend on caveo-
lae at least in some cell types. Wang et al. (18) used very high
concentrations of acceptors, which could make the contribution
of the caveolin-independent diffusion pathway of cholesterol
efflux overwhelming.
The most likely mechanism of enhanced cholesterol efflux
after overexpression of caveolin is stimulation of the flow of
2 D. Sviridov, G. Escher, and Z. Krozowski, unpublished data.
FIG. 9. ABCA1 expression in HepG2
and HepG2/cav cells. A, abundance of
ABCA1 mRNA in two cell types as deter-
mined by real-time RT-PCR; B, Western
blot of HepG2 and HepG2/cav cells using
anti-ABCA1 antibody.
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cholesterol to cholesterol-rich domains in the plasma mem-
brane. The following findings support this suggestion. (i)
Caveolae were formed as a result of transfection of HepG2 cells
with caveolin. (ii) The rate of trafficking of newly synthesized
cholesterol to cholesterol-rich domains and its efflux increased
in HepG2/cav cells. (iii) The efflux of cholesterol from plasma
membrane vesicles, where the contribution of cholesterol traf-
ficking is eliminated, was similar for the two cell types. (iv)
Progesterone, an inhibitor of intracellular cholesterol traffick-
ing, eliminated the difference in cholesterol efflux from the two
cell types. (v) The concentration of cholesterol in the endoplas-
mic reticulum decreased, as evidenced by an increase in cho-
lesterol biosynthesis and inhibition of cholesterol esterification.
The latter indicates that there is constant removal of choles-
terol from intracellular compartments. In addition, we ex-
cluded a contribution of two other obvious possibilities of an
indirect effect of transfection with caveolin: secretion of de novo
synthesized lipoproteins and expression of ABCA1. Although
there is an apparent increase in the cholesterol content in
plasma membrane cholesterol-rich domains, our data suggest
that the main mechanism of the effect of caveolin on cholesterol
efflux is stimulation of transfer of cholesterol from intracellular
compartments to cholesterol-rich domains in the plasma mem-
brane. Cholesterol in these domains can then be released to
specific extracellular acceptors if they are available or trans-
ferred to other regions in the plasma membrane (14).
In this study, we have demonstrated that transfection of
HepG2 cells with caveolin results in an increase in cholesterol
efflux. The potential benefit of increasing cholesterol efflux is
that this would prevent or slow accumulation of cholesterol in
the artery wall, preventing development of atherosclerosis.
However, the effect of caveolin appears to be cell type-specific,
and our finding may be relevant only to liver cells. Neverthe-
less, there are several ways in which overexpression of caveolin
may be exploited for the treatment of atherosclerosis. Frank et
al. (48) demonstrated that overexpression of caveolin in the
liver leads to an increase in plasma HDL concentration. Al-
though these authors attributed this to inhibition of the selec-
tive uptake of HDL cholesteryl esters, an increase in choles-
terol efflux may also contribute. Enhancement of cholesterol
efflux by overexpression of ABCA1 in the liver also leads to a
significant increase in plasma concentrations of HDL (2).
Higher plasma HDL levels may result in enhanced protection
against atherosclerosis due to either enhanced RCT or other
anti-atherogenic properties of HDL. The effects of ABCA1 and
caveolin might be additive, providing even greater protection
against atherosclerosis. The effect of caveolin transfection on
cholesterol efflux from vascular cells might depend on whether
or not transfection leads to proper intracellular distribution of
caveolin and the formation of complexes with other proteins. It
is possible that caveolin-1 might need to be cotransfected with
other genes, e.g. caveolin-2. Finally, overexpression of caveolin
leads to the inhibition of cell proliferation. This finding is
consistent with those of Fielding et al. (21) and Peterson et al.
(37) and provides another mechanism that would attenuate the
progression of atherosclerosis.
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